Another ongoing trial involving STAT3 inhibition is the phase II trial MODULATE (NCT03647839) which specifically aims to study the modulation of the tumor microenvironment using either vascular disrupting agents (BNC105) or STAT3 inhibition (BBI608), in synergy with an immune checkpoint protein (PD1) inhibitor (nivolumab). The gene discussed is STAT3; the disease is neoplasm.